References
- Cedarbaum J, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999; 169: 13–21
- Cedarbaum JM, Stambler N. Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicentric clinical trials. J Neurol Sci. 1997; 152(Suppl 1)S1–9
- Gordon PH, Miller RG, Moore DH. ALSFRS-R. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(Suppl 1)90–3
- Miller RG, Moore DH, Gelinas DF, Dronsky B, Mendoza M, Barohn R, et al. Phase II/III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001; 56: 843–8
- Leigh NP, Swash M, Iwasaki Y, Ludolph A, Meininger V, Miller RG, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotrophic Lateral Sclerosis. 2004; 5: 84–98
- Miller R, Mitchell JD, Lyon M, Moore D. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Review). Cochrane Database Syst Rev. 2007; 1, (CD001447)
- Gordon PH, Cheng B, Montes J, Doorish C, Albert SM, Mitsumoto H. Outcome measures for early phase clinical trials. Amyotrophic Lateral Sclerosis. 2007; 8: 270–3